Tag: CGUARDIANS III
First patient enrolled in InspireMD’s CGUARDIANS III pivotal study of neuro...
InspireMD today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (NPS), for...
InspireMD announces US FDA approval of IDE application for CGUARDIANS III...
InspireMD recently announced that the US Food and Drug Administration (FDA) has approved the company’s investigational device exemption (IDE) application to initiate the CGUARDIANS...
